Edition:
India

GlaxoSmithKline PLC (GSK.N)

GSK.N on New York Stock Exchange

42.28USD
16 Oct 2019
Change (% chg)

$0.01 (+0.02%)
Prev Close
$42.27
Open
$42.45
Day's High
$42.50
Day's Low
$41.87
Volume
498,683
Avg. Vol
463,723
52-wk High
$43.22
52-wk Low
$36.42

Latest Key Developments (Source: Significant Developments)

GSK Gets Positive CHMP Opinion For Intravenous Benlysta In Children With Lupus Aged 5 & Above
Friday, 20 Sep 2019 

Sept 20 (Reuters) - GlaxoSmithKline Plc ::RECEIVES POSITIVE CHMP OPINION FOR INTRAVENOUS BENLYSTA IN CHILDREN WITH LUPUS AGED FIVE YEARS AND ABOVE.CHMP OPINION FOR INTRAVENOUS BENLYSTA FOLLOWS RECENT APPROVAL BY FOOD AND DRUG ADMINISTRATION IN APRIL 2019.  Full Article

Microsoft - Charles Noski And Helmut Panke To Retire From Board - SEC Filing
Friday, 20 Sep 2019 

Sept 19 (Reuters) - Microsoft Corp ::MICROSOFT - CHARLES H. NOSKI AND HELMUT PANKE HAVE INFORMED COMPANY THEY HAVE DECIDED TO RETIRE FROM BOARD - SEC FILING.MICROSOFT - ANNOUNCED NOMINATION OF EMMA WALMSLEY, CEO OF GLAXOSMITHKLINE (GSK) AND MEMBER OF GSK BOARD, TO MICROSOFT BOARD OF DIRECTORS.MICROSOFT - ANNOUNCED NOMINATION OF EMMA WALMSLEY, CEO OF GLAXOSMITHKLINE AND MEMBER OF GSK BOARD, TO MICROSOFT BOARD OF DIRECTORS.MICROSOFT - IF WALMSLEY AND REST OF CO'S NOMINEES ARE ELECTED, BOARD WILL CONSIST OF 13 MEMBERS.  Full Article

Perrigo Advances Consumer Self-Care Growth Strategy With Acquisition Of Prevacid 24Hr
Thursday, 5 Sep 2019 

Sept 5 (Reuters) - Perrigo Company PLC ::PERRIGO ADVANCES CONSUMER SELF-CARE GROWTH STRATEGY WITH ACQUISITION OF PREVACID®24HR.PERRIGO COMPANY PLC - ACQUIRE BRANDED OTC RIGHTS TO PREVACID(®) FROM GLAXOSMITHKLINE.PERRIGO COMPANY PLC - FINANCIAL TERMS OF AGREEMENT WERE NOT DISCLOSED..PERRIGO COMPANY PLC - PERRIGO WILL HAVE EXCLUSIVE RIGHTS TO MARKET, SELL AND DISTRIBUTE PREVACID 24HR IN UNITED STATES OTC MARKET.  Full Article

GSK Says DREAMM-2 Study For Multiple Myeloma Met Main Goal
Friday, 23 Aug 2019 

Aug 23 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE PLC - GSK - POSITIVE RESULTS FROM PIVOTAL DREAMM-2 STUDY.GLAXOSMITHKLINE PLC - BELANTAMAB MAFODOTIN (GSK2857916) ON TRACK FOR REGULATORY SUBMISSION BY END OF 2019.GLAXOSMITHKLINE PLC - ANNOUNCES POSITIVE HEADLINE RESULTS FROM PIVOTAL DREAMM-2 STUDY FOR MULTIPLE MYELOMA.GSK- TWO-ARM STUDY MET PRIMARY OBJECTIVE AND DEMONSTRATED CLINICALLY MEANINGFUL OVERALL RESPONSE RATE WITH BELANTAMAB MAFODOTIN IN PATIENT POPULATION.GLAXOSMITHKLINE PLC - DATA FROM DREAMM-2 STUDY WILL BE BASIS FOR REGULATORY FILINGS STARTING LATER THIS YEAR.GLAXOSMITHKLINE PLC - SAFETY AND EFFICACY RESULTS FROM DREAMM-2 STUDY WILL BE SUBMITTED FOR PRESENTATION AT AN UPCOMING SCIENTIFIC MEETING.GLAXOSMITHKLINE PLC - SAFETY AND TOLERABILITY PROFILE WAS CONSISTENT WITH THAT OBSERVED IN DREAMM-1, FIRST TIME IN HUMAN STUDY OF BELANTAMAB MAFODOTIN.  Full Article

GSK Completes Transaction With Pfizer For New JV
Thursday, 1 Aug 2019 

Aug 1 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE PLC - GSK COMPLETES TRANSACTION WITH PFIZER FOR NEW JV.GLAXOSMITHKLINE PLC - COMPLETED ITS TRANSACTION WITH PFIZER TO COMBINE THEIR CONSUMER HEALTHCARE BUSINESSES INTO A WORLD-LEADING JOINT VENTURE.GSK - JOINT VENTURE WILL FOCUS ON COMPLETING INTEGRATION OF TWO BUSINESSES, WHICH IS EXPECTED TO REALISE ANNUAL COST SAVINGS OF £0.5BN BY 2022.  Full Article

Pfizer Announces Closing Of Joint Venture With GlaxoSmithKline
Thursday, 1 Aug 2019 

Aug 1 (Reuters) - Pfizer Inc ::PFIZER ANNOUNCES CLOSING OF JOINT VENTURE WITH GLAXOSMITHKLINE TO CREATE A PREMIER GLOBAL CONSUMER HEALTHCARE COMPANY.  Full Article

Pfizer Reports Second-Quarter 2019 Results
Monday, 29 Jul 2019 

July 29 (Reuters) - Pfizer Inc ::PFIZER REPORTS SECOND-QUARTER 2019 RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $0.80.Q2 EARNINGS PER SHARE $0.89.Q2 EARNINGS PER SHARE ESTIMATE $0.75 -- REFINITIV IBES DATA.ANNOUNCES REVERSE MORRIS TRUST TRANSACTION TO COMBINE UPJOHN AND MYLAN, CREATING A NEW GLOBAL PHARMACEUTICAL COMPANY.UPDATED 2019 FINANCIAL GUIDANCE.SEES FY REVENUE $50.5 TO $52.5 BILLION.SECOND-QUARTER 2019 UPJOHN REVENUES TOTALED $2.8 BILLION, DOWN 7% OPERATIONALLY.SEES 2019 ADJUSTED EPS OF $2.76 PER SHARE TO $2.86 PER SHARE.SECOND-QUARTER 2019 REVENUES TOTALED $13.3 BILLION, A DECREASE OF $203 MILLION, OR 2%, COMPARED TO PRIOR-YEAR QUARTER.PFIZER - DUE TO PROPOSED TRANSACTION BETWEEN CO AND MYLAN, CO'S Q2 EARNINGS CONFERENCE CALL WITH INVESTMENT ANALYSTS HAS BEEN RESCHEDULED FOR TODAY.Q2 REVENUE VIEW $13.40 BILLION -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $2.91, REVENUE VIEW $53.28 BILLION -- REFINITIV IBES DATA.SECOND-QUARTER 2019 BIOPHARMA REVENUES TOTALED $9.6 BILLION, UP 6% OPERATIONALLY.SECOND-QUARTER 2019 UPJOHN REVENUES TOTALED $2.8 BILLION, DOWN 7% OPERATIONALLY.REVENUES FOR UPJOHN IN CHINA FOR FULL YEAR ARE EXPECTED TO GROW BY LOW-TO-MID-SINGLE-DIGITS OPERATIONALLY.PFIZER-SEES NEGATIVE IMPACT OF $1.5 BILLION TO 2019 REVENUE & NEGATIVE IMPACT OF $0.03 TO 2019 ADJUSTED EPS DUE TO PENDING FORMATION OF CONSUMER HEALTHCARE JV.  Full Article

GlaxoSmithKline Posts Q2 Adjusted EPS 30.5 Pence
Wednesday, 24 Jul 2019 

July 24 (Reuters) - Glaxosmithkline Plc ::Q2 ADJUSTED EPS ROSE 9 PERCENT TO 30.5 PENCE.QTRLY TOTAL EPS 19.5P.2019 ADJUSTED EPS GUIDANCE IMPROVED TO EXPECTED DECLINE OF -3% TO -5% AT CER FROM -5% TO -9%.19P DIVIDEND DECLARED FOR QUARTER; CONTINUE TO EXPECT 80P FOR FY19.QTRLY GROUP SALES £7.8 BILLION, +7% AER, +5% CER.QTRLY ADJUSTED EPS 30.5P.NEW GUIDANCE REFLECTS IMPROVED OPERATING PERFORMANCE, LOWER INTEREST EXPENSE, ONE-OFF BENEFIT TO SHARE OF AFTER TAX PROFITS OF ASSOCIATES IN Q1.QTRLY PHARMACEUTICALS SALES £4.3 BILLION, +2% AER, -1% CER.POSITIVE CLINICAL DATA RECEIVED SO FAR THIS YEAR OFFER SIGNIFICANT NEW OPPORTUNITIES FOR PRODUCTS IN ONCOLOGY, HIV, RESPIRATORY.QTRLY VACCINES SALES £1.6 BILLION, +26% AER, +23% CER.SHINGRIX RECORDED SALES OF £386 MILLION IN THE QUARTER, DRIVEN BY CONTINUED STRONG UPTAKE IN THE US.QTRLY CONSUMER HEALTHCARE SALES £1.9 BILLION, +5% AER, +4% CER.IF EXCHANGE RATES HOLD AT CLOSING RATES ON 30 JUNE FOR REST OF 2019, ESTIMATED POSITIVE IMPACT ON 2019 STERLING TURNOVER GROWTH TO BE ABOUT 2%.EXPECT TO COMPLETE JOINT VENTURE WITH PFIZER SHORTLY.QTRLY TURNOVER INCREASED 5% CER WITH CER GROWTH DELIVERED BY VACCINES, CONSUMER HEALTHCARE PARTIALLY OFFSET BY DECLINE IN PHARMACEUTICALS.QTRLY HIV SALES £1.2 BILLION +2% AER, -2% CER.QTRLY SALES OF ESTABLISHED PHARMACEUTICALS DECLINED 6% AER, 7% CER TO £2,138 MILLION INCLUDING IMPACT OF LOSS OF EXCLUSIVITY OF ADVAIR.TOTAL MAJOR RESTRUCTURING CHARGES INCURRED IN QUARTER WERE £309 MILLION (Q2 2018: £158 MILLION).  Full Article

GSK Says Co To Announce Collaboration With Lyell Immunopharma
Wednesday, 24 Jul 2019 

July 24 (Reuters) - GlaxoSmithKline PLC ::SAYS "SHINGRIX HAD ANOTHER STANDOUT QUARTER" - CONF CALL.SAYS MORE THAN DOUBLED THE NUMBER OF ASSETS IN ONCOLOGY OVER THE LAST 12 MONTHS - MEDIA CALL.HAL BARRON SAID ON THE MEDIA CALL THAT THE COMPANY WILL ANNOUNCE A COLLABORATION WITH LYELL IMMUNOPHARMA.GSK, WITH RESPECT TO BREXIT, SAYS NOTHING HAS REALLY CHANGED AND WE CONTINUE TO PREPARE FOR ALL SCENARIOS - CONF CALL.SAYS NO-DEAL BREXIT WOULD BE A BAD SCENARIO - CONF CALL.GSK CEO, WITH RESPECT TO BREXIT, SAYS STAND READY TO WORK WITH BRITISH GOVERNMENT - CONF CALL.  Full Article

GSK Names Jonathan Symonds As Non-Executive Chairman Of Board Of Directors
Wednesday, 24 Jul 2019 

July 24 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE PLC HSBC HOLDINGS PLC - NON-EXECUTIVE CHAIRMAN.GLAXOSMITHKLINE PLC - GLAXOSMITHKLINE PLC APPOINTS JONATHAN SYMONDS AS NON-EXECUTIVE CHAIRMAN OF BOARD OF DIRECTORS.GLAXOSMITHKLINE - JONATHAN SYMONDS WILL SUCCEED SIR PHILIP HAMPTON AS NON-EXECUTIVE CHAIRMAN OF GSK BOARD.  Full Article

Photo

GSK recalls popular heartburn drug Zantac globally after cancer scare

GlaxoSmithKline on Tuesday said it is recalling the popular heartburn medicine Zantac in all markets as a "precaution", days after the U.S. Food and Drug Administration found "unacceptable" levels of probable cancer-causing impurity in the drug. | Video